Diplomat Pharmacy (DPLO) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Leerink Partners Cuts Price target on Diplomat Pharmacy (DPLO) Following Weak EPS Guide
March 1, 2016 7:23 AM ESTLeerink Partners maintained an Outperform rating on Diplomat Pharmacy (NYSE: DPLO), and cut the price target to $35.00 (from $40.00), following the company's 4Q. DPLO reported revenue of $987M, ahead of consensus' $970M. Adjusted EPS of $0.21 beat the consensus of $0.20. 2016 guidance calls for total revenue of... More



